Arxis, Inc.
ARXSArxis, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages. Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Arxis, Inc. trades at $52.0, between stages. It sits at 69% of a 52-week range of $35 to $60. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 10 straight weeks.
Today the stock is between stages. At $52.0 it trades near its long-run average and sits at 69% of its 52-week range ($35–$60).
Against the market, two honest reads. Cumulative: over the last 5 months the stock moved +37% while the S&P 500 moved +7% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Arxis, Inc. trades at 169.7× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 169.7× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Arxis, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +114.9% | — | — | — |
4-Factor Sector Score
45.4/100 — rank 24 of 30 in Electrical Equipment & Parts · 28% evidence confidence · provisional, ranked below fully-evidenced peers
Arxis, Inc. scores 45.4 out of 100 against the 30 companies it is compared with in Electrical Equipment & Parts, ranking 24. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 14.7 + 10.7 + 10 + 10 = 45.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Arxis, Inc. reported $0.5 B of revenue in the Jun 26 quarter, +25.0% year on year. That is the 2nd straight quarter of year-on-year growth. Over 2 years it has compounded at 94.6% a year. The last full year, FY25, came in at $1.6 B. The last four reported quarters add to $1.7 B.
FY25 revenue came in at $1.6 B (+114.9% on the year), capping 2 years at 94.6% compound. The latest quarter (Jun 26) printed $0.5 B, +25.0% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +23.1% growth against the decade's 94.6% — the current year is running slower than its own long-run rate.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Arxis, Inc.'s operating margin is 6.0% in the Jun 26 quarter, −14.0 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 11.9% to 18.9%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 6.0%, −14.0 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 11.9%–18.9%.
Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Arxis, Inc. earned $0.0 B of net profit in the Jun 26 quarter. Full-year FY25 profit was $0.1 B. That is 0.0% of the quarter's revenue.
Jun 26 profit was $0.0 B, null year on year. On the full year, FY25 printed $0.1 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Arxis, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $0.3 B of operating cash against $0.1 B of profit. After $0.0 B of capital spending, $0.2 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $0.3 B against reported profit of $0.1 B, leaving free cash of $0.2 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Arxis, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Arxis, Inc. earns a ROE of 2% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 3.1% net margin on 0.24× asset turns.
FY25 ROE is 2%.
Why the return is what it is — the wiring (FY25): 3.1% net margin × 0.24× asset turns × 2.12× balance-sheet leverage ≈ 1.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
Dividend
Arxis, Inc. pays no dividend. Across the last 4 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Arxis, Inc. does not currently pay a dividend. Across the last 4 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Arxis, Inc. carries total debt of $1.8 B against shareholder equity of $4.5 B as of Jun 26, a debt-to-equity of 0.40. On the annual view that ratio went from 0.88 in FY24 to 0.87 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $1.8 B against shareholder equity of $4.5 B — a debt-to-equity of 0.40. On the annual view, debt-to-equity went from 0.88 (FY24) to 0.87 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.4% of Arxis, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.4% of the float is sold short, and at typical trading volumes it would take about 4.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Arxis, Inc.: the Z-score reads 4.35. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 4.35 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 4.35.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Espey Mfg. & Electronics Corp.ESP | 66.2/100Favorable setup75% evidence | FADING | 19.4/35 Revenue -8.7% · PAT 37.5% · OPM change 9.1 pp 83% evidence | 15.6/25 ROCE 5.8% · OPM 26.1% 76% evidence | 16.0/20 P/E 14.5× · PEG 0.34 65% evidence | 15.2/20 RS sector 16.6% · RS bench 10.9% · 1Y 40.7%3 of 12 weeks ahead 70% evidence |
| Exact sum: 19.4 + 15.6 + 16 + 15.2 = 66.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2nVent Electric plcNVT | 63.9/100Mixed-positive evidence85% evidence | ASLEEP | 22.2/35 Revenue 46.2% · PAT 1.9% · OPM change 3.9 pp 95% evidence | 19.3/25 ROCE 14% · OPM 20.5% 76% evidence | 5.2/20 P/E 45.8× · PEG 4.29 65% evidence | 17.2/20 RS sector 18.5% · RS bench 12.6% · 1Y 59.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 19.3 + 5.2 + 17.2 = 63.9 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 3Bloom Energy CorporationBE | 62.1/100Mixed-positive evidence67% evidence | ASLEEP | 25.5/35 Revenue 91.1% · PAT 100% · OPM change 18 pp 71% evidence | 13.3/25 ROCE 5.5% · OPM 17.1% 76% evidence | 8.5/20 P/E 403.6× · PEG — 15% evidence | 14.8/20 RS sector 49% · RS bench 39.7% · 1Y 212.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25.5 + 13.3 + 8.5 + 14.8 = 62.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Preformed Line Products CompanyPLPC | 60.9/100Thin evidence · provisional58% evidence | BREAKING OUT | 18.5/35 Revenue — · PAT — · OPM change -1 pp 45% evidence | 13.9/25 ROCE 5.2% · OPM 7.8% 76% evidence | 9.5/20 P/E 46.2× · PEG — 15% evidence | 19.0/20 RS sector 36.3% · RS bench 29.5% · 1Y 104.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 13.9 + 9.5 + 19 = 60.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Vertiv Holdings CoVRT | 60.8/100Mixed-positive evidence75% evidence | ASLEEP | 24.5/35 Revenue 26.2% · PAT 100% · OPM change 2.7 pp 95% evidence | 16.4/25 ROCE 8.3% · OPM 19.5% 76% evidence | 9.0/20 P/E 75.8× · PEG — 15% evidence | 10.9/20 RS sector 1.3% · RS bench -4.1% · 1Y 73.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 16.4 + 9 + 10.9 = 60.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Atkore Inc.ATKR | 57.9/100Mixed-positive evidence64% evidence | BREAKING OUT | 19.1/35 Revenue -3.4% · PAT -162.5% · OPM change 8.8 pp 62% evidence | 9.7/25 ROCE 0.5% · OPM 1.4% 76% evidence | 10.2/20 P/E 22.8× · PEG — 15% evidence | 18.9/20 RS sector 27.2% · RS bench 21.8% · 1Y 56.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 9.7 + 10.2 + 18.9 = 57.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Acuity Inc.AYI | 57.2/100Mixed-positive evidence85% evidence | ASLEEP | 20.0/35 Revenue 10.5% · PAT 17.7% · OPM change 4.2 pp 95% evidence | 15.0/25 ROCE 5% · OPM 16.1% 76% evidence | 12.7/20 P/E 20.2× · PEG 1.07 65% evidence | 9.5/20 RS sector -10.5% · RS bench -13.7% · 1Y -10%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 15 + 12.7 + 9.5 = 57.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Advanced Energy Industries, Inc.AEIS | 57.1/100Mixed-positive evidence81% evidence | ASLEEP | 25.7/35 Revenue 22.2% · PAT 100% · OPM change 5.8 pp 83% evidence | 13.3/25 ROCE 3.8% · OPM 13.4% 76% evidence | 12.1/20 P/E 67.9× · PEG 0.94 65% evidence | 6.0/20 RS sector -8.2% · RS bench -12.9% · 1Y 50.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.7 + 13.3 + 12.1 + 6 = 57.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.2% and the one-year return is 50.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 9Energizer Holdings, Inc.ENR | 51.9/100Mixed-positive evidence65% evidence | ASLEEP | 18.5/35 Revenue 2.7% · PAT 100% · OPM change 1.5 pp 83% evidence | 11.8/25 ROCE 2.4% · OPM 13.5% 76% evidence | 11.3/20 P/E 6× · PEG — 15% evidence | 10.3/20 RS sector -1.3% · RS bench -4.8% · 1Y -25.8%5 of 12 weeks ahead 70% evidence |
| Exact sum: 18.5 + 11.8 + 11.3 + 10.3 = 51.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Hayward Holdings, Inc.HAYW | 50.8/100Thin evidence · provisional58% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change 2 pp 45% evidence | 13.6/25 ROCE 2.7% · OPM 16.6% 76% evidence | 10.7/20 P/E 22.3× · PEG — 15% evidence | 8.5/20 RS sector -17.8% · RS bench -20.9% · 1Y -12.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 13.6 + 10.7 + 8.5 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11EnerSysENS | 49.3/100Mixed-negative evidence81% evidence | ASLEEP | 10.7/35 Revenue 3.7% · PAT -19.8% · OPM change -1 pp 83% evidence | 13.9/25 ROCE 3.9% · OPM 12.5% 76% evidence | 14.7/20 P/E 22.6× · PEG 0.49 65% evidence | 10.0/20 RS sector -0.3% · RS bench -5.4% · 1Y 61.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 13.9 + 14.7 + 10 = 49.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Kimball Electronics, Inc.KE | 47.8/100Mixed-negative evidence75% evidence | BASING | 15.9/35 Revenue -6.3% · PAT 50% · OPM change 0.2 pp 83% evidence | 10.7/25 ROCE 1.6% · OPM 3.3% 76% evidence | 14.6/20 P/E 22.8× · PEG 0.49 65% evidence | 6.6/20 RS sector -10.6% · RS bench -13.9% · 1Y -22%0 of 12 weeks ahead 70% evidence |
| Exact sum: 15.9 + 10.7 + 14.6 + 6.6 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Hubbell IncorporatedHUBB | 45.2/100Mixed-negative evidence85% evidence | ASLEEP | 11.1/35 Revenue 10.6% · PAT 8.2% · OPM change -1.2 pp 95% evidence | 18.8/25 ROCE 12.6% · OPM 21.7% 76% evidence | 6.0/20 P/E 30.7× · PEG 3.29 65% evidence | 9.3/20 RS sector -9.2% · RS bench -13% · 1Y 1.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.1 + 18.8 + 6 + 9.3 = 45.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Electrovaya Inc.ELVA | 44.1/100Mixed-negative evidence75% evidence | BASING | 20.5/35 Revenue 50% · PAT 100% · OPM change 2.8 pp 83% evidence | 10.9/25 ROCE 3.3% · OPM 12.1% 76% evidence | 7.2/20 P/E 71.1× · PEG 2.27 65% evidence | 5.5/20 RS sector -19.2% · RS bench -23.5% · 1Y -5.6%1 of 12 weeks ahead 70% evidence |
| Exact sum: 20.5 + 10.9 + 7.2 + 5.5 = 44.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Eos Energy Enterprises, Inc.EOSE | 43.8/100Mixed-negative evidence64% evidence | BASING | 26.0/35 Revenue 100% · PAT — · OPM change 367 pp 62% evidence | 5.0/25 ROCE -18.7% · OPM -139.2% 76% evidence | 11.2/20 P/E 6.3× · PEG — 15% evidence | 1.6/20 RS sector -59.4% · RS bench -60.5% · 1Y -59.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26 + 5 + 11.2 + 1.6 = 43.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -59.4% and the one-year return is -59.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 16Amprius Technologies, Inc.AMPX | 43.1/100Mixed-negative evidence61% evidence | ASLEEP | 24.3/35 Revenue 100% · PAT — · OPM change 62.3 pp 62% evidence | 5.9/25 ROCE -6.1% · OPM -23.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -29% · RS bench -32.7% · 1Y -19.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 5.9 + 10 + 2.9 = 43.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -29% and the one-year return is -19.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 17NeoVolta Inc.NEOV | 42.1/100Thin evidence · provisional55% evidence | BREAKING OUT | 19.8/35 Revenue 100% · PAT — · OPM change -61.6 pp 62% evidence | 4.2/25 ROCE -19.4% · OPM -129.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.1/20 RS sector -6.2% · RS bench -8.8% · 1Y -40.3%6 of 12 weeks ahead 70% evidence |
| Exact sum: 19.8 + 4.2 + 10 + 8.1 = 42.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Plug Power Inc.PLUG | 40.9/100Mixed-negative evidence61% evidence | BASING | 19.3/35 Revenue 15.3% · PAT — · OPM change 66.5 pp 62% evidence | 6.2/25 ROCE -4.7% · OPM -67% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.4/20 RS sector -19.1% · RS bench -23% · 1Y -4.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 6.2 + 10 + 5.4 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19FuelCell Energy, Inc.FCEL | 39.8/100Mixed-negative evidence64% evidence | ASLEEP | 11.2/35 Revenue 31% · PAT — · OPM change -123.2 pp 71% evidence | 4.7/25 ROCE -8.9% · OPM -218.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.9/20 RS sector 43.4% · RS bench 34.7% · 1Y 116.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 4.7 + 10 + 13.9 = 39.8 · Decision use: Price leads the evidence: RS versus the benchmark is 34.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Powell Industries, Inc.POWL | 38.5/100Mixed-negative evidence81% evidence | ASLEEP | 9.7/35 Revenue 4.5% · PAT 7.5% · OPM change -1.7 pp 83% evidence | 16.3/25 ROCE 8.9% · OPM 19.4% 76% evidence | 4.8/20 P/E 35.3× · PEG 4.52 65% evidence | 7.7/20 RS sector -0.9% · RS bench -7.1% · 1Y 85.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 9.7 + 16.3 + 4.8 + 7.7 = 38.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 21T1 Energy Inc.TE | 37.8/100Thin evidence · provisional53% evidence | ASLEEP | 18.9/35 Revenue — · PAT — · OPM change 35.2 pp 39% evidence | 7.8/25 ROCE -2.5% · OPM -12.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.1/20 RS sector -30.1% · RS bench -34.1% · 1Y 113.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 7.8 + 10 + 1.1 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22GrafTech International Ltd.EAF | 31.7/100Thin evidence · provisional58% evidence | TURNING | 10.3/35 Revenue 0.6% · PAT — · OPM change -8.2 pp 62% evidence | 7.4/25 ROCE -3.2% · OPM -24.5% 76% evidence | 8.8/20 P/E 76.6× · PEG — 15% evidence | 5.2/20 RS sector -25.4% · RS bench -27.5% · 1Y -38.9%0 of 12 weeks ahead 70% evidence |
| Exact sum: 10.3 + 7.4 + 8.8 + 5.2 = 31.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Forgent Power Solutions, Inc.FPS | 45.9/100Thin evidence · provisional38% evidence | ASLEEP | 16.1/35 Revenue — · PAT — · OPM change -1.6 pp 45% evidence | 11.1/25 ROCE 2.9% · OPM 10.4% 76% evidence | 8.7/20 P/E 250.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 12 weeks ahead 0% evidence |
| Exact sum: 16.1 + 11.1 + 8.7 + 10 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Arxis, Inc.this pageARXS | 45.4/100Thin evidence · provisional28% evidence | BREAKING OUT | 14.7/35 Revenue — · PAT — · OPM change -14.2 pp 26% evidence | 10.7/25 ROCE 4.5% · OPM 6.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 10 weeks ahead 0% evidence |
| Exact sum: 14.7 + 10.7 + 10 + 10 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25ADS-TEC Energy PLCADSE | 44.0/100Thin evidence · provisional32% evidence | ASLEEP | 16.0/35 Revenue — · PAT — · OPM change — 9% evidence | 7.3/25 ROCE -30.3% · OPM — 46% evidence | 11.5/20 P/E 0.1× · PEG — 15% evidence | 9.2/20 RS sector -3.2% · RS bench -7% · 1Y 24.3%1 of 12 weeks ahead 70% evidence |
| Exact sum: 16 + 7.3 + 11.5 + 9.2 = 44 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26X-Energy, Inc.XE | 42.1/100Thin evidence · provisional28% evidence | ASLEEP | 17.6/35 Revenue — · PAT — · OPM change -25.8 pp 26% evidence | 4.5/25 ROCE -11.9% · OPM -152.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 8 weeks ahead 0% evidence |
| Exact sum: 17.6 + 4.5 + 10 + 10 = 42.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Factorial Energy Inc.FAC | 41.3/100Thin evidence · provisional18% evidence | ASLEEP | 16.1/35 Revenue — · PAT — · OPM change — 8% evidence | 5.2/25 ROCE -34.9% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y -37.7%0 of 12 weeks ahead 0% evidence |
| Exact sum: 16.1 + 5.2 + 10 + 10 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Ballard Power Systems Inc.BLDP | 41.1/100Thin evidence · provisional49% evidence | BASING | 20.0/35 Revenue — · PAT — · OPM change 118.5 pp 45% evidence | 6.6/25 ROCE -2.7% · OPM -70.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.5/20 RS sector -29.9% · RS bench -33.6% · 1Y -20.8%1 of 12 weeks ahead 70% evidence |
| Exact sum: 20 + 6.6 + 10 + 4.5 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Lightbridge CorporationLTBR | 41.0/100Thin evidence · provisional41% evidence | ASLEEP | 20.0/35 Revenue — · PAT — · OPM change — 33% evidence | 7.3/25 ROCE -5.6% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.7/20 RS sector -53.5% · RS bench -54.9% · 1Y -64.3%0 of 12 weeks ahead 70% evidence |
| Exact sum: 20 + 7.3 + 10 + 3.7 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Enovix CorporationENVX | 39.5/100Thin evidence · provisional49% evidence | ASLEEP | 20.8/35 Revenue — · PAT — · OPM change 8 pp 45% evidence | 5.3/25 ROCE -7.2% · OPM -577.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.4/20 RS sector -58% · RS bench -59.5% · 1Y -70.4%0 of 12 weeks ahead 70% evidence |
| Exact sum: 20.8 + 5.3 + 10 + 3.4 = 39.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Arxis, Inc.'s stock price today?
Arxis, Inc. trades at $52.0. The company is valued at $22.0 B. The stock sits at 69% of its 52-week range of $35–$60. Against the S&P 500 it has been ahead on a trailing-13-week view for 10 weeks. — as of 19 September 2026.
What were Arxis, Inc.'s latest quarterly results?
Arxis, Inc. reported revenue of $0.5 B and net profit of $0.0 B for the Jun 26 quarter. The operating margin was 6.0%, 14.0 pp lower than a year earlier. — as of 19 September 2026.
What is Arxis, Inc.'s revenue?
Arxis, Inc. reported revenue of $0.5 B in the Jun 26 quarter, +25.0% year on year. For the full FY25 fiscal year, revenue was $1.6 B (+114.9%). Over the last 2 years revenue compounded at 94.6% a year. — as of 19 September 2026.
What is Arxis, Inc.'s profit?
Arxis, Inc. earned $0.0 B of net profit in the Jun 26 quarter. Full-year FY25 profit was $0.1 B. The operating margin ran 6.0% in the latest quarter. — as of 19 September 2026.
What is Arxis, Inc.'s market cap?
Arxis, Inc.'s market capitalisation is $22.0 B at a stock price of $52.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 19 September 2026.
Does Arxis, Inc. pay a dividend?
No — Arxis, Inc. has declared no dividend per share in any of its last 4 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 19 September 2026.
How is Arxis, Inc. performing?
Arxis, Inc.'s latest readings are below. Against the S&P 500 it has been ahead on a trailing-13-week view for 10 weeks. This describes what the data did, not a rating. — as of 19 September 2026.
Is Arxis, Inc. beating the market?
On recent form, yes — Arxis, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 10 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5 months the stock moved +37% against the S&P 500's +7% — ahead of the index over the full window. — as of 19 September 2026.
Will Arxis, Inc.'s stock price go up?
This page publishes no price forecast for Arxis, Inc. What it measures instead: the stock price is $52.0. Direction is not something this site claims to know. — as of 19 September 2026.
Is the market betting against Arxis, Inc.?
Somewhat — short interest is 3.4% of Arxis, Inc.'s tradable float, about 4.5 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 19 September 2026.
Does Arxis, Inc. have too much debt?
It is moderate — Arxis, Inc.'s debt-to-equity is 0.40. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 19 September 2026.
What is Arxis, Inc.'s capex?
Arxis, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 19 September 2026.
What is Arxis, Inc.'s cash flow?
Arxis, Inc. generated $0.3 B of operating cash flow in FY25 and $0.2 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 19 September 2026.
How financially safe is Arxis, Inc.?
On the balance sheet, the Z-score reads 4.35 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 19 September 2026.
Where is Arxis, Inc. in its business cycle?
Arxis, Inc.'s FY25 operating margin was 18.9%, against a 3-year band of 11.9%–18.9%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 6.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 19 September 2026.
What could break the Arxis, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 19 September 2026.
Is Arxis, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Arxis, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 19 September 2026.
Not SEBI Registered !! Not Investment advice !!